Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity Post author: Post published:February 15, 2024 Post category:uncategorized Researchers evaluated rational combination treatment regimens for advanced/metastatic non-small-cell lung cancer (NSCLC). You Might Also Like Machine learning reveals secrets of aging in flies and humans October 30, 2024 New insights on how melanoma cells resist cancer immunotherapy August 27, 2024 New evidence connects ultra-processed foods to rising diabetes rates September 18, 2024